Schering-Plough Shows Off Once-Daily Hep C Drug Narlaprevir At AASLD
This article was originally published in The Pink Sheet Daily
Next-generation ritonavir-boosted protease inhibitor is headed into Phase IIb, and if all goes well, could be a significant player in the hepatitis C market.
You may also be interested in...
Is it a trick or a treat? AASLD lifts embargo on all annual meeting data at Halloween press conference.
Combination therapy with two experimental, oral, direct-acting antivirals in treatment-naïve hepatitis C patients showed significant viral-load reductions and a clean safety profile, Roche and its biotech partners on the two drugs announced April 25 during the European Association for the Study of the Liver conference in Copenhagen, Denmark
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.